[quote="JusaVaan, post:4949, topic:66933, full:true"]\nPatrick taitaa painaa vaan entteriä paljon asiaan paneutumatta. Hänellähän on kai aina ollut 10 punnan tavoitehinta, vaikka osakemäärä on kasvanut aika hurjasti tässä viime vuosina…\n[/quote]\n\nWithout taking a stance on Patrick Truchio’s price target in pounds, the increase in the number of shares and the share price means the company’s market cap grows, as it should due to progress in the trials. In addition to just hitting enter, the analysis updates do take note of BEXMAB’s results, the funding brought by the share issue for BEXERA, and state that there is a go/no-go for it at the end of 2027, as well as noting the start of BEXAR. US biotech analysts are perhaps generally more optimistic about the opportunities than Europeans. He might not take the slide in the share price into account like other analysts do. The slide in the share price does not, in itself, affect Bex’s success, but it does affect Faron’s financing.\n\n\n\nActual amounts of money, on the other hand, are examined in this post. Regarding historical upfront payments of pharmaceutical licensing agreements. Medians for realized binding upfront payments only (cash + shares), meaning it excludes subsequent milestone payments and royalties from drug sales. Publicly announced single-asset licenses. This doesn’t say Bex either, but it gives a directional indication of where things stand regarding deals.\n\n
\n\n\n\n\n\n\n\n\nBiopharma had a winter. After the flood of capital during COVID, funding tightened, partnering slowed, and pharma became much more selective about where it placed large bets. Now there are signs of… | Andy Lee
9 Likes